Innovest Global Signs Worldwide Agreement With Cedars-Sinai Medical Center to Commercialize Vaccine

StemVax Therapeutics, an Innovest Global Inc. holding, has been awarded an exclusive worldwide license agreement from Cedars-Sinai Medical Center in Los Angeles, CA, for all of the intellectual property needed to commercialize the StemVax Glioblast brain tumor vaccine.

“The StemVax business model is a low-cost, high-output strategy of partnering with a major health organization to get the technology to market and start helping people,” said Dr. Dwain Morris-Irvin, President of Innovest’s Biotech Division, the StemVax Chief Science Officer, and co-author of the intellectual property. “This agreement, which was negotiated over a 9-month period, is critical because we now has everything we need, and we have it all in house.”

Innovest announced the approved patent of the primary technology on July 25, 2018. Now, Cedars-Sinai Medical Center, the organization that filed for that patent, has provided StemVax the exclusive, worldwide right to it and three other related Intellectual Properties subsequently filed for patent protection.

“This illustrates Dr. Irvin’s status as a scientist, and is exactly the type of progress Innovest shareholders are thrilled to see. It’s progress, but it’s also just a little better than you might have thought possible,” said Dan Martin, CEO of Innovest Global. “When an organization like Cedars grants these types of rights, and Dr. Irvin’s peers and co-authors sign-off on the arrangement – these are monumental endorsements of him and StemVax. I’m honored to be a part of it, and excited that Innovest continues to engage with people and organizations that are world class.”

Cedars-Sinai Medical Center is a non-profit hospital and academic health science center located in Los Angeles, CA. They employ over 2,000 physicians and are considered one of the top hospitals and research organizations in the world. Dr. Irvin previously was one of their key contributors in the areas of research that he founded StemVax to pursue.

StemVax Therapeutics is a Translational biotechnology company that develops novel therapies for brain tumor patients. We focus our efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer. We also focus our research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells. We seek to make a difference in patient’s lives. Bringing new beginnings to the market by developing novel therapeutics.

 Innovest Global, Inc. is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Innovest Global utilizes novel technology and marketing to efficiently acquire customers. Our primary growth strategy is to acquire existing companies in a select few industries, and attract new customers in cost effective ways. Currently, we have a Commercial & Industrial Division, and a Biotechnology & Health Services Division. For more information, visit: http://www.innovestglobal.com